526139 — Transgene Biotek Share Price
0.000.00%
Last trade - 00:00- IN₹548.57m
- IN₹684.13m
- IN₹0.55m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.94 | ||
| Price to Tang. Book | 12.08 | ||
| Price to Free Cashflow | 26,159.98 | ||
| Price to Sales | 288.92 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1.44% | ||
| Return on Equity | -14.71% | ||
| Operating Margin | -998.22% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 0.71 | 0.04 | 1.7 | 0.87 | 0.55 | n/a | n/a | -14.17% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Transgene Biotek Limited is an India-based biotechnology company. The Company is engaged in the research and development of vaccines, oncology and new drug delivery technologies. Its portfolio of products includes oncology, auto-immunity, drug delivery and biogenerics. The Company offers TrabiAAV, which is a platform for the delivery of micro ribonucleic acids (miRNAs), short hairpin RNA (ShRNAs), immunogens developing clinical significance in gene therapy and CRISPR/cas 9 technologies. Its monoclonal antibody therapy is the use of monoclonal antibodies to specifically bind to target cells. Its TrabiORAL is focused on delivering proteins and peptides orally for a variety of human diseases. Its TBL-1203, is used to strengthen cell-mediated immunity and complete elimination of the human immunodeficiency virus (HIV), without any need for retroviral drug therapy. Its Tacrolimus is a drug that suppresses the immune system and is mainly used to prevent rejection of transplanted organs.
Directors
- K. Koteswara Rao MDR
- Shyam Das DRC (46)
- Vikram Polavarapu DRC
- Sarang Puranik DRC (35)
- P. Ghosh IND
- Soma Marthi IND
- L. Sujana IND
- G. Santosh Kumar NID
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 1st, 1990
- Public Since
- September 23rd, 1992
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Bombay Stock Exchange
- Shares in Issue
- 75,770,001
- Address
- C-44, Madhuranagar, S R Nagar, HYDERABAD, 502315
- Web
- https://www.transgenebiotek.com/
- Phone
- +91 8458279744
- Auditors
- Manisha Dubey & Associates
Upcoming Events for 526139
Q1 2025 Transgene Biotek Ltd Earnings Release
Similar to 526139
Chemo Pharma Laboratories
Bombay Stock Exchange
Indo US Bio-Tech
Bombay Stock Exchange
Jeevan Scientific Technology
Bombay Stock Exchange
Shree Ganesh Remedies
Bombay Stock Exchange
Vanta Bioscience
Bombay Stock Exchange
FAQ
What is the Transgene Biotek share price?
As of Today at 19:22 UTC, shares in Transgene Biotek are trading at IN₹7.24. This share price information is delayed by 15 minutes.
How has the Transgene Biotek share price performed this year?
Shares in Transgene Biotek last closed at IN₹7.24 and the price had moved by +144.59% over the past 365 days. In terms of relative price strength the Transgene Biotek share price has outperformed the S&P BSE 100 Index by +90.02% over the past year.
What are the analyst and broker recommendations for Transgene Biotek?
There is no consensus recommendation for this security.
What is the Transgene Biotek dividend yield?
Transgene Biotek does not currently pay a dividend.
Does Transgene Biotek pay a dividend?
Transgene Biotek does not currently pay a dividend.
When does Transgene Biotek next pay dividends?
Transgene Biotek does not currently pay a dividend.
How do I buy Transgene Biotek shares?
To buy shares in Transgene Biotek you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Transgene Biotek?
As of the previous close price of IN₹7.24, shares in Transgene Biotek had a market capitalisation of IN₹548.57m.
Where are Transgene Biotek shares listed?
Here are the trading details for Transgene Biotek:
- Country of listing: India
- Exchange: BSE
- Ticker Symbol: 526139
What kind of share is Transgene Biotek?
Based on an overall assessment of its quality, value and momentum Transgene Biotek is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Transgene Biotek share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Transgene Biotek share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Transgene Biotek. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +36.32%.
As of the last closing price of IN₹7.24, shares in Transgene Biotek were trading +0.76% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Transgene Biotek PE Ratio?
The Transgene Biotek PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹7.24.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Transgene Biotek?
Transgene Biotek's management team is headed by:
- K. Koteswara Rao - MDR
- Shyam Das - DRC
- Vikram Polavarapu - DRC
- Sarang Puranik - DRC
- P. Ghosh - IND
- Soma Marthi - IND
- L. Sujana - IND
- G. Santosh Kumar - NID